In order to strengthen its immuno-oncology pipeline, Janssen Biotech has agreed to pay US$100 M upfront and committed up to US$1.188 B more to access Xencor’s bispecific antibody, plamotamab, and its XmAb® CD28 bispecific antibodies combinations. These candidates have the potential to redefine the treatment landscape for B-cell lymphoma patients, transitioning away from the standard chemotherapy regimens. The deal comes nearly a year after the two companies collaborated on the development of Xencor’s XmAb® CD28 bispecific antibodies for the treatment of prostate cancer.